Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069460 | 1.00 | POLB (0.68) | POLBL3MBTL1HPGDTP53ATM | |
| SCHEMBL5781007 | 1.00 | POLB (0.68) | POLBL3MBTL1HPGDTP53ATM | |
| SCHEMBL5970008 | 0.86 | ALDH1A1 (0.62) | L3MBTL1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL2584810 | 0.86 | ALDH1A1 (0.62) | L3MBTL1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL14662009 | 0.85 | SMN1; SMN2 (0.65) | POLBL3MBTL1HPGDTP53ATM | |
| SCHEMBL843091 | 0.85 | SMN1; SMN2 (0.77) | POLBL3MBTL1HPGDTP53ATM | |
| SCHEMBL1263215 | 0.85 | SMN1; SMN2 (0.77) | POLBL3MBTL1HPGDTP53ATM | |
| SCHEMBL5390794 | 0.85 | SMN1; SMN2 (0.77) | POLBL3MBTL1HPGDTP53ATM | |
| SCHEMBL6646180 | 0.84 | POLB (0.74) | POLBL3MBTL1HPGDTP53SMN1; SMN2 | |
| SCHEMBL14990930 | 0.83 | BRD4 (0.69) | POLBL3MBTL1HPGDSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455482-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-7977327-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-1987034-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmceuticals Incorporated (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| WO-2007100670-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1757598-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | AQP1, GLUL, GATD3 | POLB 24/4885L3MBTL1 2601/4885HPGD 578/4885 |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | QPCT, GMPS, QPCTL | POLB 67/4885L3MBTL1 3444/4885HPGD 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.